BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 7603456)

  • 21. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P; Prigent AF; Lagarde M; Nemoz G
    Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A role for cyclic nucleotide phosphodiesterase 4 in regulation of the growth of human malignant melanoma cells.
    Narita M; Murata T; Shimizu K; Nakagawa T; Sugiyama T; Inui M; Hiramoto K; Tagawa T
    Oncol Rep; 2007 May; 17(5):1133-9. PubMed ID: 17390056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of a mutation in phosphodiesterase type 4 that alters both inhibitor activity and nucleotide selectivity.
    Herman SB; Juilfs DM; Fauman EB; Juneau P; Menetski JP
    Mol Pharmacol; 2000 May; 57(5):991-9. PubMed ID: 10779384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.
    Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
    Cell Signal; 2001 Mar; 13(3):159-67. PubMed ID: 11282454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
    Kelly JJ; Barnes PJ; Giembycz MA
    Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Profiling of functional phosphodiesterase in mesangial cells using a CRE-SEAP-based reporting system.
    Zhu Y; Yao J; Meng Y; Kasai A; Hiramatsu N; Hayakawa K; Miida T; Takeda M; Okada M; Kitamura M
    Br J Pharmacol; 2006 Jul; 148(6):833-44. PubMed ID: 16751794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
    Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
    Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
    Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.
    Netherton SJ; Maurice DH
    Mol Pharmacol; 2005 Jan; 67(1):263-72. PubMed ID: 15475573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TcPDE4, a novel membrane-associated cAMP-specific phosphodiesterase from Trypanosoma cruzi.
    Alonso GD; Schoijet AC; Torres HN; Flawiá MM
    Mol Biochem Parasitol; 2006 Jan; 145(1):40-9. PubMed ID: 16225937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.
    MacKenzie SJ; Houslay MD
    Biochem J; 2000 Apr; 347(Pt 2):571-8. PubMed ID: 10749688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes.
    Smith SJ; Cieslinski LB; Newton R; Donnelly LE; Fenwick PS; Nicholson AG; Barnes PJ; Barnette MS; Giembycz MA
    Mol Pharmacol; 2004 Dec; 66(6):1679-89. PubMed ID: 15371556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple cyclic nucleotide phosphodiesterases in human trabecular meshwork cells.
    Zhou L; Thompson WJ; Potter DE
    Invest Ophthalmol Vis Sci; 1999 Jul; 40(8):1745-52. PubMed ID: 10393044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes.
    Kerfant BG; Zhao D; Lorenzen-Schmidt I; Wilson LS; Cai S; Chen SR; Maurice DH; Backx PH
    Circ Res; 2007 Aug; 101(4):400-8. PubMed ID: 17615371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain.
    Iona S; Cuomo M; Bushnik T; Naro F; Sette C; Hess M; Shelton ER; Conti M
    Mol Pharmacol; 1998 Jan; 53(1):23-32. PubMed ID: 9443929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene.
    Bolger GB; Erdogan S; Jones RE; Loughney K; Scotland G; Hoffmann R; Wilkinson I; Farrell C; Houslay MD
    Biochem J; 1997 Dec; 328 ( Pt 2)(Pt 2):539-48. PubMed ID: 9371713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney.
    Dousa TP
    Kidney Int; 1999 Jan; 55(1):29-62. PubMed ID: 9893113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective up-regulation of phosphodiesterase-4 cyclic adenosine 3',5'-monophosphate (cAMP)-specific phosphodiesterase variants by elevated cAMP content in human myometrial cells in culture.
    Méhats C; Tanguy G; Dallot E; Robert B; Rebourcet R; Ferré F; Leroy MJ
    Endocrinology; 1999 Jul; 140(7):3228-37. PubMed ID: 10385419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant.
    Erdogan S; Houslay MD
    Biochem J; 1997 Jan; 321 ( Pt 1)(Pt 1):165-75. PubMed ID: 9003416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.